Major added benefit of Radium-223 dichloride for certain prostate cancer patients
Patients survive longer and get bone symptoms later / no evaluable data in comparison with docetaxelRadium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases.
New test could accurately predict prostate cancer recurrence
Researchers have created a test that they say can predict whether a man is at high risk of prostate cancer recurrence.The research team, led by Prof. Robert Bristow of the Princess Margaret Cancer Centre and the University of Toronto, both in Canada, presented their findings at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna, Italy.
Medication does not help prevent erectile dysfunction following radiation therapy for prostate cancer
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in JAMA. Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer treatment.
MRI helps diagnose prostate cancer more accurately
In a world first, an Australian clinical trial has shown that biopsy guided by MRI can significantly improve the diagnosis of life-threatening prostate cancer and reduce the over-diagnosis of non-life-threatening cases, thus avoiding the side effects of unnecessary treatment.
Predicting prostate cancer survival by measuring circulating tumor cells
New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA).The research was published in the Journal of Clinical Oncology by a team led by Amir Goldkorn, M.D.
Most men with early prostate cancer do not benefit from primary androgen deprivation therapy
A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.
Discovery of gene family that suppress prostate cancer
Cornell researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.The study is published in the journal Cell Reports.Previous research at Cornell and elsewhere has shown that another gene, called p53, acts to positively regulate miR-34. Mutations of p53 have been implicated in half of all cancers.
Risk of prostate cancer death decreased by PSA-testing and early treatment
Mortality in prostate cancer is lower in areas with frequent use of PSA testing compared with areas with little testing shows a study published online in Journal of the National Cancer Institute by researchers from Umeå University, Sweden and Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Convenient, less expensive, but possibly riskier new prostate cancer treatment: SBRT
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers - a higher rate of urinary complications.The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT).
Prostate cancer outcomes predicted by bone turnover markers: findings could influence treatment and clinical trial design
Biomarkers for bone formation and resorption predict outcomes for men with castration-resistant prostate cancer, a team of researchers from UC Davis and their collaborators have found. Their study, published online in the Journal of the National Cancer Institute, also found that the markers identified a small group of patients who responded to the investigational drug atrasentan.